chevron_leftBack
As of 13 June 2026, 2seventy bio, Inc. has a market cap of $266.15M USD, ranking #19316 globally and #3203 in the United States.
It ranks #1735 in the Healthcare sector, and #331 in the Biotechnology industry.
Key Stats
Market Cap
$266.15MUSD
Enterprise Value
$332.55MUSD
Revenue (TTM)
$48.37MUSD
EBITDA (TTM)
-$52.72MUSD
Net Income (TTM)
-$4.09MUSD
EBITDA Margin
-109%
Profit Margin
-8.5%
PS Ratio
5.4
PB Ratio
1.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
William Baird
open_in_new
Employees
65
Founded
2021
Website
2seventybio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0% | 0.2% | 0.8% | 109% | 17% | 14% |
News
Loading...
TSVT Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
TSVT
2seventy bio Inc Ordinary Shares
ISIN: US9013841070
Shares Out.:
Shares Outstanding:
53.23M1
Shares Float:
48.264M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
5.00 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About 2seventy bio, Inc.
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company’s products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
68K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
60K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
10K%
|
-
|
|
NYSE: IQV
|
$26.3B
10K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
9K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
7K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
18K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
17K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
16K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
16K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
10K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
10K%
|
-
|
chevron_leftBack